L
Longieva develops novel therapeutics targeting GPCRs for brain disorders, focusing on Substance Use Disorders and Neuroinflammatory Diseases. The company engineers safe and effective small molecule GPCR agonists to address these conditions. Their most advanced candidate is currently in preclinical IND-enabling studies with a projected Phase I trial initiation by late 2025.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Longieva develops novel therapeutics targeting GPCRs for brain disorders, focusing on Substance Use Disorders and Neuroinflammatory Diseases. The company engineers safe and effective small molecule GPCR agonists to address these conditions. Their most advanced candidate is currently in preclinical IND-enabling studies with a projected Phase I trial initiation by late 2025.